Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers.
about
Targeting the ubiquitin pathway for cancer treatmentOne-shot NMR analysis of microbial secretions identifies highly potent proteasome inhibitorBlocking autophagy prevents bortezomib-induced NF-κB activation by reducing I-κBα degradation in lymphoma cellsTriptolide inhibits the proliferation of prostate cancer cells and down-regulates SUMO-specific protease 1 expressionTargeting neuroblastoma stem cells with retinoic acid and proteasome inhibitorChemotherapy-induced neuropathies-a growing problem for patients and health care providersEvolving Therapies and FAK Inhibitors for the Treatment of CancerTargeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumabDiscovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cellsDevelopment of HIF-1 inhibitors for cancer therapyBasic leucine zipper protein Cnc-C is a substrate and transcriptional regulator of the Drosophila 26S proteasome.The boron-oxygen core of borinate esters is responsible for the store-operated calcium entry potentiation ability.Epidermal growth factor receptor vIII expression in U87 glioblastoma cells alters their proteasome composition, function, and response to irradiation.Proteasome inhibitor bortezomib ameliorates intestinal injury in mice.The risk factors for herpes zoster in bortezomib treatment in patients with multiple myelomaInhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomibMurraya koenigii leaf extract inhibits proteasome activity and induces cell death in breast cancer cells.Effect of immunoglobulin therapy on the rate of infections in multiple myeloma patients undergoing autologous stem cell transplantation or treated with immunomodulatory agentsCancerous inhibitor of protein phosphatase 2A mediates bortezomib-induced autophagy in hepatocellular carcinoma independent of proteasome.Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines.Small molecule screen reveals regulation of survival motor neuron protein abundance by Ras proteins.Inhibition of Nek2 by small molecules affects proteasome activity.Bortezomib-based vs non-bortezomib-based post-transplantation treatment in multiple myeloma patients: a systematic review and meta-analysis of Phase III randomized controlled trialsThe ubiquitin-proteasome system as a prospective molecular target for cancer treatment and prevention.Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.HIF-1α pathway: role, regulation and intervention for cancer therapy.FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis.Broad targeting of resistance to apoptosis in cancer.Proteasome inhibitor bortezomib for the treatment of multiple myeloma.Ophthalmic manifestations of herpes zoster virus in patients with multiple myeloma following bone marrow transplantation.Emodin potentiates the antiproliferative effect of interferon α/β by activation of JAK/STAT pathway signaling through inhibition of the 26S proteasomeIncorporation of biologic therapies in the management of gastroesophageal cancersA Bowman-Birk inhibitor induces apoptosis in human breast adenocarcinoma through mitochondrial impairment and oxidative damage following proteasome 20S inhibitionRadiosensitization of noradrenaline transporter-expressing tumour cells by proteasome inhibitors and the role of reactive oxygen speciesPhase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma.Treatment of multiple myeloma in the targeted therapy era.Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: basic and clinical aspectsProteasome inhibitors - molecular basis and current perspectives in multiple myeloma.Bortezomib could down-regulate the expression of RANKL, inhibit cell proliferation and induce cell apoptosis in the human myeloma cell line RPMI 8226 by activating casepase-3.
P2860
Q26866185-17988BFC-F661-4FF6-ABCB-619B733A4E01Q27674685-66B4C6FB-7572-4214-93B1-7E9B28450228Q28481321-C212BAAB-A147-4AEC-BDCA-E1CC229A0E99Q28484018-3839CD5D-EDCA-4C6B-922A-0457073F1213Q28534151-C2814B8D-D77D-46C4-B7AC-54A9CB4EDDC1Q28818565-B1B410E6-BC2C-4336-90AE-EDB5EE200424Q28972291-4D134FE4-669B-4CF1-915D-F3643E637C7BQ33418562-58DA1496-7F6B-423D-87DF-640241FE8D02Q33453188-26955888-7917-459D-B4A4-1DEAFEA84B59Q33703381-D654691E-1623-4583-936A-F3590BE624B7Q33768364-B59E6C8B-DE66-48DF-8E4D-30A15DA57FF0Q33803509-53AC02D2-D146-4429-8CF0-EBC4A80A4F72Q33880422-590EC37F-A14B-4799-B6F3-3154EFD9B547Q34222685-834A6CD2-0CF9-4B44-B070-E73AA7186C29Q34316960-B6459FF1-8749-4025-A42A-7F8528586834Q34332019-0AF19E0E-E0DE-4D70-BC3D-B5BEDA018707Q34542978-05CF37A3-097B-4141-A88B-D49DC073A0D1Q34549211-47AC54EA-D691-4FA6-8327-8F1C2661D827Q34577215-72F6AD65-7AB9-4B34-A418-E8E0D8ACF504Q34604658-D99F4F73-8A35-4B83-8F35-4508215ECD52Q34614482-F19519B3-D997-4E36-B40D-AB2150DCD2B1Q34621731-CF682A01-1D7C-4124-88A3-6E6E6A5F5DC4Q35329864-D0B1802E-5953-4CDD-8852-BC9BB278743EQ35760754-B7C76B09-BEF2-49AC-A319-CCA727B00FBBQ35836872-7756C725-A034-4C78-B08C-692884DA1B9DQ35836881-BEDAADD9-2D9D-4246-B750-6C191920B160Q36238647-5F3787F6-BBEF-432C-B713-7F4C034500A3Q36334327-6514BA3F-E96B-4F27-9743-92C96C11D4E1Q36483749-7D6FB7C0-CC8C-456A-8C3D-912DD7F66CEDQ36523911-1E8D4013-C5E6-42D5-9C7E-C11BEBBE1CF5Q36703679-888D60FF-FCCC-4C6E-897A-319BF0F42A79Q36782542-3DAE8002-DE85-4430-84A4-66D0D64694D0Q37141676-EA64EFB0-44E3-4ABD-BC7B-D5B3157D24A1Q37164347-F70071D9-577C-4C4C-83BA-09BA054C3423Q37309407-AA40539F-D54C-4D15-955B-D599EFBBE443Q37321943-46FB80F8-1B67-4B29-932D-DE1FF697A4E6Q37385547-936D878F-19D0-4E00-BDFB-D552D6A278D0Q37948056-71783357-4BAF-46E4-87BD-9D644D63A108Q38202977-9AB0E9E4-97C9-4E8A-BEF8-D8678B99957CQ38693406-F55A83B3-A0AD-4CE7-A22A-7EE80970161B
P2860
Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Bortezomib (PS-341): a novel, ...... ple myeloma and other cancers.
@ast
Bortezomib (PS-341): a novel, ...... ple myeloma and other cancers.
@en
type
label
Bortezomib (PS-341): a novel, ...... ple myeloma and other cancers.
@ast
Bortezomib (PS-341): a novel, ...... ple myeloma and other cancers.
@en
prefLabel
Bortezomib (PS-341): a novel, ...... ple myeloma and other cancers.
@ast
Bortezomib (PS-341): a novel, ...... ple myeloma and other cancers.
@en
P1433
P1476
Bortezomib (PS-341): a novel, ...... ple myeloma and other cancers.
@en
P2093
Teru Hideshima
P304
P356
10.1177/107327480301000502
P577
2003-09-01T00:00:00Z